Pulmonx Co. (NASDAQ:LUNG) CEO Steven S. Williamson Sells 27,689 Shares

Pulmonx Co. (NASDAQ:LUNG) CEO Steven S. Williamson sold 27,689 shares of the firm’s stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $7.14, for a total value of $197,699.46. Following the transaction, the chief executive officer now owns 194,342 shares in the company, valued at $1,387,601.88. The trade was a 12.47 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Pulmonx Stock Down 5.5 %

Shares of NASDAQ LUNG opened at $8.19 on Thursday. The company has a current ratio of 7.70, a quick ratio of 6.77 and a debt-to-equity ratio of 0.40. The stock has a market capitalization of $325.93 million, a PE ratio of -5.69 and a beta of 0.50. The stock’s fifty day simple moving average is $6.93 and its two-hundred day simple moving average is $6.93. Pulmonx Co. has a 12-month low of $5.46 and a 12-month high of $10.01.

Pulmonx (NASDAQ:LUNG) last posted its quarterly earnings data on Wednesday, February 19th. The company reported ($0.33) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.12. The firm had revenue of $23.77 million during the quarter, compared to analysts’ expectations of $22.29 million. Pulmonx had a negative return on equity of 55.36% and a negative net margin of 67.31%. As a group, analysts expect that Pulmonx Co. will post -1.55 EPS for the current fiscal year.

Analyst Ratings Changes

Several research firms have commented on LUNG. Wells Fargo & Company reduced their price objective on Pulmonx from $10.00 to $8.00 and set an “equal weight” rating on the stock in a report on Wednesday, December 11th. Citigroup restated a “neutral” rating and set a $7.50 price objective (down from $17.00) on shares of Pulmonx in a report on Wednesday, December 11th. Two analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $12.75.

Institutional Trading of Pulmonx

Institutional investors have recently made changes to their positions in the business. Mackenzie Financial Corp acquired a new stake in Pulmonx during the 4th quarter worth about $372,000. ProShare Advisors LLC acquired a new stake in Pulmonx in the 4th quarter worth about $72,000. Millennium Management LLC boosted its holdings in Pulmonx by 26.6% in the 4th quarter. Millennium Management LLC now owns 183,069 shares of the company’s stock worth $1,243,000 after buying an additional 38,425 shares during the last quarter. Graham Capital Management L.P. boosted its holdings in Pulmonx by 73.3% in the 4th quarter. Graham Capital Management L.P. now owns 18,071 shares of the company’s stock worth $123,000 after buying an additional 7,641 shares during the last quarter. Finally, D. E. Shaw & Co. Inc. boosted its holdings in shares of Pulmonx by 8.9% during the 4th quarter. D. E. Shaw & Co. Inc. now owns 392,836 shares of the company’s stock worth $2,667,000 after purchasing an additional 32,049 shares during the last quarter. Institutional investors and hedge funds own 91.04% of the company’s stock.

Pulmonx Company Profile

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.